Pathogenic roles of macrophage migration inhibitory factor during dengue virus infection

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Chuang, Yung Chun ^a   Chen, Hong Ru ^a   Yeh, Trai Ming ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE MIGRATION INHIBITION FACTOR; ISOMERASE; MIF PROTEIN, HUMAN;

BLOOD VESSEL PERMEABILITY; DENGUE; DISEASE SEVERITY; ENDOTHELIUM CELL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; VIRUS REPLICATION; ANIMAL; CAPILLARY PERMEABILITY; CHEMISTRY; DENGUE VIRUS; IMMUNOLOGY; INFLAMMATION; MOUSE; PHYSIOLOGY;

DENGUE VIRUS; MUS;

ANIMALS; CAPILLARY PERMEABILITY; DENGUE; DENGUE VIRUS; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; VIRUS REPLICATION;

EID: 84925308694     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/547094     Document Type: Review

References (68)

1. J. R. David, "Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction," Proceedings of the National Academy of Sciences of the United States of America, vol. 56, no. 1, pp. 72-77, 1966.
2. B. R. Bloomand B. Bennett, "Mechanism of a reaction in vitro associated with delayed-type hypersensitivity," Science, vol. 153, no. 3731, pp. 80-82, 1966.
3. Y. Asare, M. Schmitt, and J. Bernhagen, "The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis," Thrombosis and Haemostasis, vol. 109, no. 3, pp. 391-398, 2013.
4. H.-W. Sun, J. Bernhagen, R. Bucala, and E. Lolis, "Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 11, pp. 5191-5196, 1996.
5. T. Calandra, J. Bernhagen, R. A. Mitchell, and R. Bucala, "Themacrophage is an important and previously unrecognized source of macrophage migration inhibitory factor," The Journal of Experimental Medicine, vol. 179, no. 6, pp. 1895-1902, 1994.
6. T. Kumagi, F. Akbar, N. Horiike, and M. Onji, "Increased serum levels of macrophage migration inhibitory factor in alcoholic liver diseases and their expression in liver tissues," Clinical Biochemistry, vol. 34, no. 3, pp. 189-193, 2001.
7. R. S. Gomez, T. L. Diepgen, C. Neumann, and C. Sorg, "Detection of migration inhibitory factor (MIF) by a monoclonal antibody in the microvasculature of inflamed skin," Archives of Dermatological Research, vol. 282, no. 6, pp. 374-378, 1990.
8. T. Calandra and T. Roger, "Macrophage migration inhibitory factor: a regulator of innate immunity," Nature Reviews Immunology, vol. 3, no. 10, pp. 791-800, 2003.
9. T. Calandra, J. Bernhagen, C. N. Metz et al., "MIF as a glucocorticoid-induced modulator of cytokine production," Nature, vol. 377, no. 6544, pp. 68-71, 1995.
10. T. Calandra and R. Bucala, "Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock," Journal of Inflammation, vol. 47, no. 1-2, pp. 39-51, 1995.
11. S. C. Donnelly and R. Bucala, "Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease," Molecular Medicine Today, vol. 3, no. 11, pp. 502-507, 1997.
12. T. Strüßmann, S. Tillmann, T. Wirtz, R. Bucala, P. von Hundelshausen, and J. Bernhagen, "Platelets are a previously unrecognised source of MIF," Thrombosis and Haemostasis, vol. 110, no. 5, pp. 1004-1013, 2013.
13. L. Leng, C. N. Metz, Y. Fang et al., "MIF signal transduction initiated by binding to CD74," The Journal of Experimental Medicine, vol. 197, no. 11, pp. 1467-1476, 2003.
14. X. Shi, L. Leng, T. Wang et al., "CD44is the signalingcomponent of the macrophage migration inhibitory factor-CD74 receptor complex," Immunity, vol. 25, no. 4, pp. 595-606, 2006.
15. M. Tarnowski, K. Grymula, R. Liu et al., "Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts," Molecular Cancer Research, vol. 8, no. 10, pp. 1328-1343, 2010.
16. V. Schwartz, H. Lue, S. Kraemer et al., "A functional heteromeric MIF receptor formed by CD74 and CXCR4," FEBS Letters, vol. 583, no. 17, pp. 2749-2757, 2009.
17. H. Lue, A. Kapurniotu, G. Fingerle-Rowson et al., "Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity," Cellular Signalling, vol. 18, no. 5, pp. 688-703, 2006.
18. H. Lue, M. Thiele, J. Franz et al., "Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity," Oncogene, vol. 26, no. 35, pp. 5046-5059, 2007.
19. J. Bernhagen, R. Krohn, H. Lue et al., "MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment," Nature Medicine, vol. 13, no. 5, pp. 587-596, 2007.
20. M. Chatterjee, O. Borst, B. Walker et al., "Macrophagemigration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent akt signaling," Circulation Research, vol. 115, no. 11, pp. 939-949, 2014.
21. R. Kleemann, A. Hausser, G. Geiger et al., "Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1," Nature, vol. 408, no. 6809, pp. 211-216, 2000.
22. E. F. Morand and M. Leech, "Macrophage migration inhibitory factor in rheumatoid arthritis," Frontiers in Bioscience, vol. 10, no. 1, pp. 12-22, 2005.
23. J. Bernhagen, T. Calandra, R. A. Mitchell et al., "MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia," Nature, vol. 365, no. 6448, pp. 756-759, 1993.
24. M. Bozza, A. R. Satoskar, G. Lin et al., "Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis," The Journal of Experimental Medicine, vol. 189, no. 2, pp. 341-346, 1999.
25. F. A. Bozza, R. N. Gomes, A. M. Japiassú et al., "Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis," Shock, vol. 22, no. 4, pp. 309-313, 2004.
26. Y. Al-Abed, D. Dabideen, B. Aljabari et al., "ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis," The Journal of Biological Chemistry, vol. 280, no. 44, pp. 36541-36544, 2005.
27. T. Calandra, B. Echtenacher, D. Le Roy et al., "Protection from septic shock by neutralization of macrophage migration inhibitory factor," Nature Medicine, vol. 6, no. 2, pp. 164-170, 2000.
28. M. G. Cavalcanti, J. S. Mesquita, K. Madi et al., "Mif participates in Toxoplasma gondii-induced pathology following oral infection," PLoS ONE, vol. 6, no. 9, Article ID e25259, 2011.
29. C. Herder, T. Illig, J. Baumert et al., "Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002," Atherosclerosis, vol. 200, no. 2, pp. 380-388, 2008.
30. I. I. Müller, K. A. L. Müller, H. Schönleber et al., "Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response," PloS ONE, vol. 7, no. 6, Article ID e38376, 2012.
31. A. Zernecke, J. Bernhagen, and C. Weber, "Macrophage migration inhibitory factor in cardiovascular disease," Circulation, vol. 117, no. 12, pp. 1594-1602, 2008.
32. K. D. Simpson, D. J. Templeton, and J. V. Cross, "Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducingmyeloid-derived suppressor cells in the tumor microenvironment," The Journal of Immunology, vol. 189, no. 12, pp. 5533-5540, 2012.
33. E.F. Morand, M. Leech, and J. Bernhagen, "MIF: a newcytokine link between rheumatoid arthritis and atherosclerosis," Nature Reviews Drug Discovery, vol. 5, no. 5, pp. 399-411, 2006.
34. X. Xu, B. D. Pacheco, L. Leng, R. Bucala, and J. Ren, "Macrophage migration inhibitory factor plays a permissive role in the maintenance of cardiac contractile function under starvation through regulation of autophagy," Cardiovascular Research, vol. 99, no. 3, pp. 412-421, 2013.
35. X. Q. Hou, Y. W. Gao, S. T. Yang, C. Y. Wang, Z. Y. Ma, and X. Z. Xia, "Role of macrophage migration inhibitory factor in influenza H5N1 virus pneumonia," Acta Virologica, vol. 53, no. 4, pp. 225-231, 2009.
36. J. Delaloye, I. J. A. de Bruin, K. E. A. Darling et al., "Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection," Cytokine, vol. 60, no. 2, pp. 338-340, 2012.
37. N. Wauquier, P. Becquart, C. Padilla, S. Baize, and E. M. Leroy, "Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis," PLoS Neglected Tropical Diseases, vol. 4, no. 10, article e837, 2010.
38. I. Assunção-Miranda, F. A. Amaral, F. A. Bozza et al., "Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection," The FASEB Journal, vol. 24, no. 1, pp. 218-228, 2010.
39. L.-C. Chen, H.-Y. Lei, C.-C. Liu et al., "Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients," American Journal of Tropical Medicine and Hygiene, vol. 74, no. 1, pp. 142-147, 2006.
40. E. A. Henchal and J. R. Putnak, "The dengue viruses," Clinical Microbiology Reviews, vol. 3, no. 4, pp. 376-396, 1990.
41. S. B. Halstead and E. J. O'Rourke, "Antibody enhanced dengue virus infection in primate leukocytes," Nature, vol. 265, pp. 739-741, 1977.
42. A. L. Rothman and F. A. Ennis, "Immunopathogenesis of dengue hemorrhagic fever," Virology, vol. 257, no. 1, pp. 1-6, 1999.
43. H.-Y. Lei, T.-M. Yeh, H.-S. Liu, Y.-S. Lin, S.-H. Chen, and C.-C. Liu, "Immunopathogenesis of dengue virus infection," Journal of Biomedical Science, vol. 8, no. 5, pp. 377-388, 2001.
44. V. A. Bokisch, F. H. Top Jr., P. K. Russell, F. J. Dixon, and H. J. Müller-Eberhard, "The potential pathogenic role of complement in dengue hemorrhagic shock syndrome," The New England Journal of Medicine, vol. 289, no. 19, pp. 996-1000, 1973.
45. Y.-C. Chuang, H.-Y. Lei, H.-S. Liu, Y.-S. Lin, T.-F. Fu, and T.-M. Yeh, "Macrophage migration inhibitory factor induced by dengue virus infection increases vascular permeability," Cytokine, vol. 54, no. 2, pp. 222-231, 2011.
46. L.-C. Chen, H.-W. Shyu, H.-Y. Lei et al., "Dengue virus infection induced NF-κB-dependent macrophage migration inhibitory factor production," The American Journal of Infectious Diseases, vol. 4, no. 1, pp. 22-31, 2008.
47. T. Chareonsirisuthigul, S. Kalayanarooj, and S. Ubol, "Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells," Journal of General Virology, vol. 88, no. 2, pp. 365-375, 2007.
48. E. G. Regis, V. Barreto-de-Souza, M. G. Morgado et al., "Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication," Virology, vol. 399, no. 1, pp. 31-38, 2010.
49. L. J. Herrero, M. Nelson, A. Srikiatkhachorn et al., "Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 29, pp. 12048-12053, 2011.
50. A. Arjona, H. G. Foellmer, T. Town et al., "Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion," The Journal of Clinical Investigation, vol. 117, no. 10, pp. 3059-3066, 2007.
51. Y.-R. Lee, H.-Y. Lei, M.-T. Liu et al., "Autophagic machinery activated by dengue virus enhances virus replication," Virology, vol. 374, no. 2, pp. 240-248, 2008.
52. N. S. Heaton and G. Randall, "Dengue virus-induced autophagy regulates lipid metabolism," Cell Host and Microbe, vol. 8, no. 5, pp. 422-432, 2010.
53. Y.-R. Lee, H.-Y. Hu, S.-H. Kuo et al., "Dengue virus infection induces autophagy: an in vivo study," Journal of Biomedical Science, vol. 20, no. 1, article 65, 2013.
54. M. Djavaheri-Mergny, M. Amelotti, J. Mathieu et al., "NF- κB activation represses tumor necrosis factor-α-induced autophagy," The Journal of Biological Chemistry, vol. 281, no. 41, pp. 30373-30382, 2006.
55. J. Harris, "Autophagy and cytokines," Cytokine, vol. 56, no. 2, pp. 140-144, 2011.
56. H.-J. Park, S. J. Lee, S.-H. Kim et al., "IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway," Molecular Immunology, vol. 48, no. 4, pp. 720-727, 2011.
57. Y.-C. Chuang, W.-H. Su, H.-Y. Lei et al., "Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation," PLoS ONE, vol. 7, no. 5, Article ID e37613, 2012.
58. C. A. Aveleira, C.-M. Lin, S. F. Abcouwer, A. F. Ambrósio, and D. A. Antonetti, "TNF-α signals through PKCξ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability," Diabetes, vol. 59, no. 11, pp. 2872-2882, 2010.
59. S. Hofmann, H. Grasberger, P. Jung et al., "The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression," European Journal of Medical Research, vol. 7, no. 4, pp. 171-176, 2002.
60. J. Gavard and J. S. Gutkind, "VEGF Controls endothelial-cell permeability promoting β-arrestin-dependent endocytosis VEcadherin," Nature Cell Biology, vol. 8, no. 11, pp. 1223-1234, 2006.
61. S. Huveneers, J. Oldenburg, E. Spanjaard et al., "Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling," Journal of Cell Biology, vol. 196, no. 5, pp. 641-652, 2012.
62. W. Zhu, N. R. London, C. C. Gibson et al., "Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability," Nature, vol. 492, no. 7428, pp. 252-255, 2012.
63. H. R. Chen, Y. C. Chuang, C. H. Chao, and T. M. Yeh, "Macrophage migration inhibitory factor induces vascular leakage via autophagy," Biology Open, vol. 4, no. 2, pp. 244-252, 2015.
64. M. A. Amin, C. S. Haas, K. Zhu et al., "Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFκB," Blood, vol. 107, no. 6, pp. 2252-2261, 2006.
65. L.-Y. Shyu, T.-M. Yeh, H.-H. Chang et al., "Macrophage migration inhibitory factor induces ICAM-1and thrombomobulin expression in vitro," Thrombosis Research, vol. 129, no. 1, pp. 43-49, 2012.
66. T.-M. Yeh, S.-H. Liu, K.-C. Lin et al., "Dengue virus enhances thrombomodulin and ICAM-1 expression through the macrophage migration inhibitory factor induction of the MAPK and PI3K signaling pathways," PLoS ONE, vol. 8, no. 1, Article ID e55018, 2013.
67. P. Butthep, S. Chunhakan, K. Tangnararatchakit, S. Yoksan, K. Pattanapanyasat, and A. Chuansumrit, "Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome," The Pediatric Infectious Disease Journal, vol. 25, no. 10, pp. 894-897, 2006.
68. E. F. Morand, "New therapeutic target in inflammatory disease: macrophage migration inhibitory factor," Internal Medicine Journal, vol. 35, no. 7, pp. 419-426, 2005.